MALARIA An Overview
Incidence <ul><li>Malaria is a common and life-threatening disease in many tropical and subtropical areas and is currently...
 
<ul><li>Region wise Status :- </li></ul>
South East Asia   <ul><li>1.  INDONESIA   </li></ul><ul><li>Capital : Jakarta </li></ul><ul><li>Malaria :  malaria risk ex...
<ul><li>3.  MYANMAR (FORMERLY BURMA) </li></ul><ul><li>Capital   Yangon </li></ul><ul><li>Malaria:   Malaria risk—predomin...
SAARC Countries <ul><li>1. Sri Lanka </li></ul><ul><li>Capital:   Colombo Malaria:   Malaria risk—predominantly due to P. ...
East and Central AFRICA <ul><li>1.  ANGOLA </li></ul><ul><li>Capital:   Luanda </li></ul><ul><li>Malaria:   Malaria risk—p...
<ul><li>3.  ETHIOPIA </li></ul><ul><li>Capital   Addis Ababa </li></ul><ul><li>Malaria :  Malaria risk—predominantly due t...
<ul><li>4.  KENYA </li></ul><ul><li>Capital:  Nairobi </li></ul><ul><li>Malaria :  Malaria risk—predominantly due to  </li...
<ul><li>5.  MOZAMBIQUE </li></ul><ul><li>Capital  Maputo </li></ul><ul><li>Malaria:  Malaria risk—predominantly due to P. ...
<ul><li>7.  MADAGASCAR </li></ul><ul><li>Capital :  Antananarivo </li></ul><ul><li>Malaria :  Malaria risk—predominantly d...
<ul><li>8 . TANZANIA </li></ul><ul><li>Capital :  Dodoma </li></ul><ul><li>Malaria:   Malaria risk—predominantly due  </li...
Franco Phonic Africa <ul><li>1.  BENIN </li></ul><ul><li>Capital   Porto-Novo (constitutional) / </li></ul><ul><li>Cotonou...
<ul><li>2.  BURKINA FASO </li></ul><ul><li>Capital   Ouagadougou </li></ul><ul><li>Malaria :  Malaria risk—predominantly d...
<ul><li>3.  CHAD </li></ul><ul><li>Capital :  N’Djamena </li></ul><ul><li>Malaria :  Malaria risk-predominantly due to P.f...
<ul><li>4.   GUINEA </li></ul><ul><li>Capital   Conakry </li></ul><ul><li>Malaria:   Malaria risk—predominantly due to P. ...
<ul><li>5. TOGO </li></ul><ul><li>Capital :  Lomé </li></ul><ul><li>Malaria :  Malaria risk—predominantly due to  </li></u...
<ul><li>6. SENEGAL </li></ul><ul><li>Capital:   Dakar </li></ul><ul><li>Malaria:   Malaria risk—predominantly due to P. fa...
 
MENA Countries   <ul><li>1.  EGYPT </li></ul><ul><li>Capital   Cairo </li></ul><ul><li>Malaria:   Malaria risk—predominant...
<ul><li>2. SAUDI ARABIA </li></ul><ul><li>Capital   Riyadh </li></ul><ul><li>Malaria:   Malaria risk—predominantly due to ...
<ul><li>4. TURKEY </li></ul><ul><li>Capital   Ankara </li></ul><ul><li>Malaria:   Malaria risk—exclusively due to P. vivax...
Second Phase <ul><li>1.  VIETNAM </li></ul><ul><li>Capital :  Hanoi </li></ul><ul><li>Malaria :   Malaria risk—predominant...
<ul><li>3.  SUDAN </li></ul><ul><li>Capital   Khartoum </li></ul><ul><li>Malaria:   Malaria risk—predominantly due to P. f...
<ul><li>5. ZAMBIA </li></ul><ul><li>Capital   Lusaka </li></ul><ul><li>Market information:   </li></ul><ul><li>Population ...
<ul><li>7.  CONGO </li></ul><ul><li>Capital   Brazzaville </li></ul><ul><li>Malaria:   Malaria risk—predominantly due to P...
<ul><li>THANK YOU </li></ul><ul><li>Please send your feedback to: </li></ul><ul><li>Priyank Dubey </li></ul><ul><li>Applic...
Upcoming SlideShare
Loading in …5
×

Malaria Incidence and business oppurunity

1,242 views

Published on

Published in: Business, Health & Medicine
1 Comment
0 Likes
Statistics
Notes
  • It is very useful.
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • Be the first to like this

No Downloads
Views
Total views
1,242
On SlideShare
0
From Embeds
0
Number of Embeds
25
Actions
Shares
0
Downloads
34
Comments
1
Likes
0
Embeds 0
No embeds

No notes for slide

Malaria Incidence and business oppurunity

  1. 1. MALARIA An Overview
  2. 2. Incidence <ul><li>Malaria is a common and life-threatening disease in many tropical and subtropical areas and is currently endemic in over 100 countries. </li></ul><ul><li>Worldwide there are up to 30- 50 crore cases of malaria each year; out of which 27 lakh die of it. </li></ul><ul><li>According to WHO, more than 90% of the deaths of African children are due to malaria, which kills an African child in every 10 seconds. </li></ul><ul><li>Malaria is caused by a protozoan known as plasmodium, among the hundreds of species of which only four are known to affect humans, these are- P. vivax, P. falciparum, P. Ovule, P.malariae. </li></ul>
  3. 4. <ul><li>Region wise Status :- </li></ul>
  4. 5. South East Asia <ul><li>1. INDONESIA </li></ul><ul><li>Capital : Jakarta </li></ul><ul><li>Malaria : malaria risk exists all throughout the year in the whole country except Jakarta municipality, big cities, and within the areas of tourist resorts of Bali & Java. P. falciparum resistant to chloroquine and sulfadoxine–pyrimethamine reported. P. vivax resistant to chloroquine reported. </li></ul><ul><li>2. MALAYSIA </li></ul><ul><li>Capital: Kuala Lumpur </li></ul><ul><li>Malaria: Malaria risk exists only in limited foci in the deep hinterland. Urban and coastal areas are free from malaria. P. falciparum throughout the year. P. falciparum resistant to chloroquine and sulfadoxine-pyrimethamine reported. </li></ul>
  5. 6. <ul><li>3. MYANMAR (FORMERLY BURMA) </li></ul><ul><li>Capital Yangon </li></ul><ul><li>Malaria: Malaria risk—predominantly due toP. falciparum—exists throughout the year at altitudes below 1000 m, excluding the main urban areas of Yangon and Mandalay. Risk is highest in remote rural, hilly and forest areas. P. falciparum resistant to chloroquine and sulfadoxine pyrimethamine reported. Mefloquine resistance. </li></ul><ul><li>4. THAILAND </li></ul><ul><li>Capital: Bangkok </li></ul><ul><li>Malaria: Malaria risk exists throughout the year in rural, especially forested and hilly, areas of the whole country, mainly towards the international borders. There is no risk in cities and the main tourist resorts (e.g. Bangkok, Chiangmai, Pattaya,Phuket, Samui). P. falciparum resistant to chloroquine and sulfadoxine–pyrimethamine reported. Resistance to mefloquine and to quinine reported from areas near the borders with Cambodia and Myanmar. </li></ul>
  6. 7. SAARC Countries <ul><li>1. Sri Lanka </li></ul><ul><li>Capital: Colombo Malaria: Malaria risk—predominantly due to P. falciparum—exists throughout the year in all low veld areas (mainly Big Bend, Mhlume, Simunye and Tshaneni). Chloroquine-resistant P. falciparum reported. </li></ul>
  7. 8. East and Central AFRICA <ul><li>1. ANGOLA </li></ul><ul><li>Capital: Luanda </li></ul><ul><li>Malaria: Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country. P. falciparum resistant to chloroquine and sulfadoxine – pyrimethamine reported. </li></ul><ul><li>Market Information:- </li></ul><ul><li># Population : 13,931,155. </li></ul><ul><li># The transmission season is from October to October . </li></ul><ul><li>2. CAMEROON </li></ul><ul><li>Capital: Yaoundé </li></ul><ul><li>Malaria: Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country. P. falciparum resistant to chloroquine and sulfadoxine–pyrimethamine reported. </li></ul><ul><li>Market Information: </li></ul><ul><li># Population : 8,376,571 </li></ul>
  8. 9. <ul><li>3. ETHIOPIA </li></ul><ul><li>Capital Addis Ababa </li></ul><ul><li>Malaria : Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country below 2000 m. P. falciparum resistance to chloroquine and sulfadoxine-pyrimethamine reported. There is no malaria risk in Addis Ababa. </li></ul><ul><li>Market information : </li></ul><ul><li># Population : 65,976,703 (2002). </li></ul><ul><li># The Global Fund has approved an amount of US$ 37,915,012 to reduce Malaria in Ethiopia for a period of two years. </li></ul>
  9. 10. <ul><li>4. KENYA </li></ul><ul><li>Capital: Nairobi </li></ul><ul><li>Malaria : Malaria risk—predominantly due to </li></ul><ul><li>P. falciparum—exists throughout the year in the </li></ul><ul><li>whole country. There is normally little risk in the </li></ul><ul><li>city of Nairobi and in the highlands (above 2500 </li></ul><ul><li>m) of Central, Eastern, Nyanza, Rift Valley and </li></ul><ul><li>Western provinces. P. falciparum resistant to </li></ul><ul><li>chloroquine and sulfadoxine–pyrimethamine </li></ul><ul><li>reported. </li></ul><ul><li>Market Information : </li></ul><ul><li># Population a: 32,020,244. </li></ul><ul><li># The Global Fund has approved an amount of </li></ul><ul><li>US$ 10,526,880 for a period of two years for the </li></ul><ul><li>project submitted by Kenya to address and reduce </li></ul><ul><li>the impact of malaria. </li></ul><ul><li># Population at Risk of malaria 100% </li></ul>
  10. 11. <ul><li>5. MOZAMBIQUE </li></ul><ul><li>Capital Maputo </li></ul><ul><li>Malaria: Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country. P. falciparum resistant to chloroquine and sulfadoxine – pyrimethamine reported. </li></ul><ul><li>Market Information: </li></ul><ul><li>Population: 19,034,729. </li></ul><ul><li>Global Fund support to fight Malaria: </li></ul><ul><ul><li>The Global Fund has approved an amount of US$ 12,273,573 for a period of two years to accelerate </li></ul></ul><ul><ul><li>access to prevention, care, support and treatment for persons affected with malaria. Mozambique is also </li></ul></ul><ul><ul><li>part of the Multi-Country Southern Africa (South Africa Mozambique, Swaziland) support from the Global </li></ul></ul><ul><ul><li>Fund through the project &quot;Malaria Control in the Lubombo Spatial Development Initiative Area&quot;. They </li></ul></ul><ul><ul><li>received US$7,424,815 for a period of two years. </li></ul></ul><ul><li>Malaria Transmission Season: </li></ul><ul><li>The duration of malaria transmission is 2-9 months across the country, from November to July. There is no area where the transmission is all year. </li></ul><ul><li>6. NIGERIA </li></ul><ul><li>Capital Abuja </li></ul><ul><li>Malaria: Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country. P. falciparum resistant to chloroquine and sulfadoxine–pyrimethamine reported. </li></ul><ul><li>Present status : Talks are going on with new contact for the distribution of Diagnostic products. </li></ul>
  11. 12. <ul><li>7. MADAGASCAR </li></ul><ul><li>Capital : Antananarivo </li></ul><ul><li>Malaria : Malaria risk—predominantly due to </li></ul><ul><li>P. falciparum—exists throughout the year in the </li></ul><ul><li>whole country, with the highest risk in the coasta </li></ul><ul><li>l areas. Resistance to chloroquine </li></ul><ul><li>reported. </li></ul><ul><li>Market Information:- </li></ul><ul><li># Population : 16,959,026. </li></ul><ul><li># The Global Fund has approved an amount of </li></ul><ul><li>US$ 1,500,000 for a period of two years for the </li></ul><ul><li>prevention of malaria through Social Marketing in </li></ul><ul><li>Madagascar. </li></ul><ul><li># Population at Risk of malaria 100% </li></ul>
  12. 13. <ul><li>8 . TANZANIA </li></ul><ul><li>Capital : Dodoma </li></ul><ul><li>Malaria: Malaria risk—predominantly due </li></ul><ul><li>to P. falciparum—exists throughout the year </li></ul><ul><li>in the whole country below 1800 m. </li></ul><ul><li>Market Information : </li></ul><ul><li># Population : 36,968,928. </li></ul><ul><li># Global Fund support to fight Malaria: </li></ul><ul><li>The Global Fund has also approved an amount </li></ul><ul><li>of US$781,220 for a period of two years for </li></ul><ul><li>the project for the implementation of new malaria </li></ul><ul><li>treatment policy in Zanzibar. </li></ul><ul><li># Population at Risk of malaria 100% </li></ul>
  13. 14. Franco Phonic Africa <ul><li>1. BENIN </li></ul><ul><li>Capital Porto-Novo (constitutional) / </li></ul><ul><li>Cotonou (seat of Government) </li></ul><ul><li>Malaria: Malaria risk—predominantly due to P. f </li></ul><ul><li>exists throughout the year in the whole country. Resistance </li></ul><ul><li>to chloroquine and sulfadoxine - pyrimethamine reported. </li></ul><ul><li>Market Information: </li></ul><ul><li>Population: 6,752,569 (2002) </li></ul><ul><li>Population at Risk of malaria is 100% </li></ul><ul><li>The Global Fund has approved an amount of </li></ul><ul><li>US$ 2,389,185 to accelerate the fight against malaria </li></ul><ul><li>within the context of Roll Back Malaria Programme in </li></ul><ul><li>Benin for two years. </li></ul>
  14. 15. <ul><li>2. BURKINA FASO </li></ul><ul><li>Capital Ouagadougou </li></ul><ul><li>Malaria : Malaria risk—predominantly due to P. falciparum </li></ul><ul><li>exists throughout the year in the whole country. Resistance </li></ul><ul><li>to chloroquine and sulfadoxine-pyrimethamine </li></ul><ul><li>reported. </li></ul><ul><li>Market information : </li></ul><ul><li># Population : 12,251,743 (2002) </li></ul><ul><li># Population at Risk of malaria N/A. </li></ul><ul><li># The Global Fund has approved an amount of </li></ul><ul><li>US$ 7,499,088 to enhance the control of Malaria </li></ul><ul><li>in Burkina Faso for a period of two years. </li></ul>
  15. 16. <ul><li>3. CHAD </li></ul><ul><li>Capital : N’Djamena </li></ul><ul><li>Malaria : Malaria risk-predominantly due to P.f </li></ul><ul><li>exists throughout the year in the whole country. </li></ul><ul><li>Resistance to chloroquine and sulfadoxine- </li></ul><ul><li>pyrimethamine reported. </li></ul><ul><li>Market Information : </li></ul><ul><li># Population : 8,376,571 (2002) </li></ul><ul><li># Population at Risk of malaria: N/A </li></ul><ul><li># Global Fund support to fight MALARIA, </li></ul><ul><li>the country has applied for the third round. </li></ul>
  16. 17. <ul><li>4. GUINEA </li></ul><ul><li>Capital Conakry </li></ul><ul><li>Malaria: Malaria risk—predominantly due to P. f </li></ul><ul><li>— exists throughout the year in the parts of the interior. </li></ul><ul><li>Sporadic cases of malaria have been reported from the </li></ul><ul><li>densely populated coastal belt. Chloroquine-resistant </li></ul><ul><li>P. falciparum reported. </li></ul><ul><li>Market Information: </li></ul><ul><li># Population a: 8,436,910 (2002). </li></ul><ul><li># The Global Fund has approved an amount of US </li></ul><ul><li>$ 6,893,509 to strengthen the fight against Malaria </li></ul><ul><li>in Guinea for a period of two years. </li></ul>
  17. 18. <ul><li>5. TOGO </li></ul><ul><li>Capital : Lomé </li></ul><ul><li>Malaria : Malaria risk—predominantly due to </li></ul><ul><li>P. falciparum—exists throughout the year in the </li></ul><ul><li>whole country. Chloroquine resistant P. falciparum </li></ul><ul><li>reported. </li></ul><ul><li>Market Information : </li></ul><ul><li># Population : 4,780,339. </li></ul><ul><li># Population at Risk of malaria: 100% </li></ul><ul><li># Global Fund support to fight Malaria, the country </li></ul><ul><li>has applied for the third round. </li></ul>
  18. 19. <ul><li>6. SENEGAL </li></ul><ul><li>Capital: Dakar </li></ul><ul><li>Malaria: Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country. There is less risk from January through June in the central western regions. Resistance to chloroquine and sulfadoxine– pyrimethamine reported. </li></ul>
  19. 21. MENA Countries <ul><li>1. EGYPT </li></ul><ul><li>Capital Cairo </li></ul><ul><li>Malaria: Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country below 2200 m. There is no risk in Asmara. Resistance to chloroquine and sulfadoxine-pyrimethanine reported. </li></ul>
  20. 22. <ul><li>2. SAUDI ARABIA </li></ul><ul><li>Capital Riyadh </li></ul><ul><li>Malaria: Malaria risk—predominantly due to P. falciparum—exists throughout the year in most of the Southern Region (except in the high-altitude areas of Asir Province) and in certain rural areas of the Western Region. No risk in Mecca or Medina cities. Chloroquine-resistant P. falciparum reported. </li></ul><ul><li>3. YEMEN </li></ul><ul><li>Capital Sana’a </li></ul><ul><li>Malaria : Malaria risk—predominantly due to P. falciparum—exists throughout the year, but mainly from September through February, in the whole country below 2000 m. There is no risk in Sana’a city. Resistance to chloroquine reported. </li></ul>
  21. 23. <ul><li>4. TURKEY </li></ul><ul><li>Capital Ankara </li></ul><ul><li>Malaria: Malaria risk—exclusively due to P. vivax—exists from May to October mainly in the south-eastern part of the country, and in Amikova and Çukurova Plain. There is no malaria risk in the main tourist areas in the west and southwest of the country. </li></ul>
  22. 24. Second Phase <ul><li>1. VIETNAM </li></ul><ul><li>Capital : Hanoi </li></ul><ul><li>Malaria : Malaria risk—predominantly due to P. falciparum—exists in the whole country, excluding urban centers, the Red River delta, and the coastal plain areas of central Viet Nam. High risk areas are the highland areas below 1500 m south of 18°N, notably the three central highlands provinces of Dak Lak, Gia Lai and Kon Tum, as well as the southern provinces of Ca Mau, Bac Lieu, and Tay Ninh. Resistance to chloroquine, sulfadoxine-pyrimethamine and mefloquine reported. </li></ul><ul><li>2. GHANA </li></ul><ul><li>Capital Accra </li></ul><ul><li>Malaria risk —predominantly due to P. falciparum—exists throughout the year in the whole country. Resistance to chloroquine and sulfadoxine–pyrimethamine reported. </li></ul>
  23. 25. <ul><li>3. SUDAN </li></ul><ul><li>Capital Khartoum </li></ul><ul><li>Malaria: Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country. Risk is low and seasonal in the north. It is higher along the Nile south of Lake Nasser and in the central and southern part of the country. Malaria risk on the Red Sea coast is very limited. P. falciparum resistant to chloroquine and sulfadoxine–pyrimethamine reported. </li></ul><ul><li>4. UGANDA </li></ul><ul><li>Capital Kampala </li></ul><ul><li>Malaria: Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country including the main towns of Fort Portal, Jinja, Kampala, Mbale and parts of Kigezi. Resistance to chloroquine and sulfadoxine–pyrimethamine reported. </li></ul>
  24. 26. <ul><li>5. ZAMBIA </li></ul><ul><li>Capital Lusaka </li></ul><ul><li>Market information: </li></ul><ul><li>Population : 10,905,879. </li></ul><ul><li>Global Fund support to fight Malaria: The Global Fund has approved an amount of US$ 17,892,000 for a period of two years for the project submitted by Zambia. </li></ul><ul><li>Malaria: Malaria risk—predominantly due to P.falciparam—exists throughout the year in the whole country. Resistance to chloroquine and sulfadoxine–pyrimethamine reported. </li></ul><ul><li>6. ZIMBABWE </li></ul><ul><li>Capital Harare </li></ul><ul><li>Market Information: </li></ul><ul><li>Population :13,142,283. </li></ul><ul><li>Global Fund support to fight Malaria : The Global Fund has approved an amount of US$ 6,716,250 for a period of two years for the project submitted by Zimbabwe to prevent mortality and reduce morbidity, social and economic losses due to Malaria. </li></ul><ul><li>Malaria risk —predominantly due to P. falciparum—exists from November through June in areas below 1200 m and throughout the by the year in the Zambezi valley. In Harare and Bulawayo, the risk is negligible. Resistance to chloroquine and sulfadoxine-pyrimethamine reported. </li></ul>
  25. 27. <ul><li>7. CONGO </li></ul><ul><li>Capital Brazzaville </li></ul><ul><li>Malaria: Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country. Resistance to chloroquine and sulfadoxine-pyrimethamine reported. </li></ul><ul><li>Market Information:- </li></ul><ul><li># Population : 3,203,662 </li></ul><ul><li># Malaria Risk - Population at Risk of malaria 100% </li></ul><ul><li>8. CONGO, DEMOCRATIC REPUBLIC OF THE (formerly ZAIRE) </li></ul><ul><li>Capital Kinshasa </li></ul><ul><li>Malaria: Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country. Resistance to chloroquine and sulfadoxine–pyrimethamine reported. </li></ul><ul><li>Market Information: </li></ul><ul><li># Population a: 54,440,8162 </li></ul>
  26. 28. <ul><li>THANK YOU </li></ul><ul><li>Please send your feedback to: </li></ul><ul><li>Priyank Dubey </li></ul><ul><li>Application Specialist </li></ul><ul><li>09999990845 </li></ul><ul><li>[email_address] </li></ul>

×